Over the past five years, many operators in the Brand Name Pharmaceutical Manufacturing industry contended with intensifying competition from biosimilars produced by generic manufacturers, as well as intensifying market competition. In response, many brand name manufacturers expanded their product portfolios to include biotechnology, particularly biologic drugs. This class of drugs is driven by innovation and typically benefits from greater patent protection. While some companies struck deals with generic drug providers, government and private health insurance providers, to address mounting healthcare costs, attempted to stimulate generic drug use by setting favorable reimbursement rates for generic drugs, threatening overall industry growth. Over the five years to 2023, many pharmaceutical manufacturers are expected to drive sales volumes from biologic drugs, while also raising prices on widely used specialty drugs.
Pharmaceutical manufacturers develop prescription and over-the-counter products that are used to prevent or treat illnesses in humans or animals. Brand name drugs and medication have patent protection. This industry does not include nutritional supplement or cosmetic product manufacturers.
This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.